Phage Futures Europe | Kisaco Research
Progressing phage therapy to treat acute and chronic infections safely and economically
Brussels, Belgium
25-26 September, 2019
Download Agenda
The Audience
Register

Why Attend

The inaugural Phage Futures Congress 2019 in Washington D.C was the first of its kind to discuss how to translate phage-based application in to clinically and commercially viable therapeutics.

This September, the Phage Futures Congress lands in Europe to once again bring together representatives from established biotech companies (from human and animal applications), new adopters, key academic researchers and big pharma. You’ll take away actionable insights on:

  • Preclinical data of phage therapy applications in acute and chronic indications
  • The importance of magistral preparation for the personalised model
  • Regulatory guidance to achieve data via magistral preparation or fixed cocktail methods
  • The impact of phage on the immune system
  • Administering phage therapy to overcome the current unmet medical need.
  • Investment drivers

"Investors and industry are displaying increased in interest in phage as a therapeutic modality. This conference is an unique opportunity to learn of this exciting modality." Assaf Oron, Chief Business Officer, BiomX

Past attendees

TALK TO OUR SPEAKERS ABOUT...

1. How to design a successful phage clinical trial

2. How to manipulate the microbiome with phage therapy to treat chronic diseases

3. The implications and safety requirements of administering phage therapy to patients

4. What indications are suitable for phage therapy within Europe?

5. How to obtain broad phage host range and maintain synergy within a fixed cocktail

6. Applications of phage related products as an alternative strategy to access the market 

7. How magistral preparative supports the personalised medicine method

8. The route to appropriate clinical data: through innovative trial design

9. How to alleviate future multi-drug resistance through phage evolution research

10. What are the commercial pathways for phage therapies?

TESTIMONIALS

Who Will Be There

30%
Biotech
15%
Pharma
30%
Academics
10%
Regulatory & Government Authorities
5%
Clinicians & Physicians
10%
Service Providers

Biotech

Pharma

Academics

Regulatory & Government Authorities

Clinicians & Physicians

Service Providers

SPEAKERS INCLUDE

 

Dr Harald Brusseow

KU Leuven, Group of Gene Technology

Dr Harald Brusseow

KU Leuven, Group of Gene Technology

Dr Harald Brusseow

KU Leuven, Group of Gene Technology
 

Ard Struijs

Erasmus University Medical Center

Ard Struijs

Erasmus University Medical Center

Ard Struijs

Erasmus University Medical Center
 

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx
 

Dr Christine Rohde

Curator AD Bacteriophages
DSMZ

Dr Christine Rohde

Curator AD Bacteriophages
DSMZ

Dr Christine Rohde

Curator AD Bacteriophages
DSMZ
 

Dr. Krystyna Dabrowska

Phage Biologist
Bacteriophage Laboratory, Polish Academy of Sciences

Dr. Krystyna Dabrowska

Phage Biologist
Bacteriophage Laboratory, Polish Academy of Sciences

Dr. Krystyna Dabrowska

Phage Biologist
Bacteriophage Laboratory, Polish Academy of Sciences
 

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

Dr. Bob Blasdel

Research Director
Vesale Pharma

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

I spend a lot of time thinking about what I'm going to eat next, why cows tend to orient themselves on a north/south axis, whether viruses are alive or non-living (or undead!), what it could have really been like to have lived under the laws of Solon, structure/function arguments in biology, and the value that I like to pretend the Oxford comma has for ameliorating run-on sentences.

 

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed
 

Michel de Baar

Executive Director, BD&L Europe
MSD

Michel de Baar

Executive Director, BD&L Europe
MSD

Michel de Baar

Executive Director, BD&L Europe
MSD
 

Eric Pelfrene

Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division
EMA

I am employed at the European Medicines Agency (EMA), with responsibilities mainly focused on regulatory guidance pertaining new antibacterial products and medicines for use against WHO target infections, such as malaria.  At EMA we are looking at the lifecycle of each product, through registration and post-authorisation phase, ensuring safe and effective medicines with certified quality to be available for patients throughout the European UnionThe Agency also plays a role in supporting research and innovation in the pharmaceutical sector and pr

Eric Pelfrene

Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division
EMA

Eric Pelfrene

Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division
EMA

I am employed at the European Medicines Agency (EMA), with responsibilities mainly focused on regulatory guidance pertaining new antibacterial products and medicines for use against WHO target infections, such as malaria.  At EMA we are looking at the lifecycle of each product, through registration and post-authorisation phase, ensuring safe and effective medicines with certified quality to be available for patients throughout the European UnionThe Agency also plays a role in supporting research and innovation in the pharmaceutical sector and promotes innovation and development of new medicines by European micro- small- and medium-sized-enterprises.

 

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital
 

Dr Sofia Corte-Real

Scientific Consultant
Technophage

Dr Sofia Corte-Real

Scientific Consultant
Technophage

Dr Sofia Corte-Real

Scientific Consultant
Technophage
 

Dr Pieter-Jan Ceyssens

Unit Head ‘Antibiotics & Resistance’
Sciensano

Dr Pieter-Jan Ceyssens

Unit Head ‘Antibiotics & Resistance’
Sciensano

Dr Pieter-Jan Ceyssens

Unit Head ‘Antibiotics & Resistance’
Sciensano
 

Dr Aleksandra Petrovic Fabijan

Phage Biologist
The Westmead Institute for Medical Research

Dr Aleksandra Petrovic Fabijan

Phage Biologist
The Westmead Institute for Medical Research

Dr Aleksandra Petrovic Fabijan

Phage Biologist
The Westmead Institute for Medical Research
 

Dr Gregory Resch

Project Director - Head of bacteriophage research
University of Lausanne

Dr Gregory Resch

Project Director - Head of bacteriophage research
University of Lausanne

Dr Gregory Resch

Project Director - Head of bacteriophage research
University of Lausanne
 

Dr Miguel Baretto-Sanz

Founder
Phages4A

Our company Phages4A (Phages For All) has developed a technology based on artificial intelligence, able to predict in an in-silico way (via computer simulation) the phages that can specifically infect and kill a bacteria.  Our technology harnesses the genome of phages and bacteria and relies on bacterial-phage interaction databases to train artificial intelligence algorithms. The models thus developed make it possible to select the phages that can specifically infect and kill a given bacteria.

Dr Miguel Baretto-Sanz

Founder
Phages4A

Dr Miguel Baretto-Sanz

Founder
Phages4A

Our company Phages4A (Phages For All) has developed a technology based on artificial intelligence, able to predict in an in-silico way (via computer simulation) the phages that can specifically infect and kill a bacteria.  Our technology harnesses the genome of phages and bacteria and relies on bacterial-phage interaction databases to train artificial intelligence algorithms. The models thus developed make it possible to select the phages that can specifically infect and kill a given bacteria. Our predictions help to create custom bacteriophage cocktails to treat patients with bacterial infections.

 

More specifically we aim to:

  • Help companies working on phage therapy to speed their processes to identify host range
  • Provide to hospitals and clinics with software tools to accelerate the treatment of patients suffering of diseases related antibiotic-resistant bacteria.
  • Bring our products and services to other industries including but not limited to food safety, aquaculture, veterinary, and agriculture where bacteria resistant to antibiotics is an important issue.
 

Dr Steven Hagens

Principal Scientist
Micreos

After 22 years working with phages both in academia and industry my role is to act as interface between  Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.

Dr Steven Hagens

Principal Scientist
Micreos

Dr Steven Hagens

Principal Scientist
Micreos

After 22 years working with phages both in academia and industry my role is to act as interface between  Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.

 

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center
 

Dr Ronen Hazan

Lab Head
Hebrew University

Dr Ronen Hazan

Lab Head
Hebrew University

Dr Ronen Hazan

Lab Head
Hebrew University
 

Kristin Wannerberger

R&D Alliance Management
Ferring Pharmaceuticals

Kristin Wannerberger

R&D Alliance Management
Ferring Pharmaceuticals

Kristin Wannerberger

R&D Alliance Management
Ferring Pharmaceuticals
 

Prof Christian Willy

Professor of Surgery
German Military Hospital Berlin

Prof Christian Willy

Professor of Surgery
German Military Hospital Berlin

Prof Christian Willy

Professor of Surgery
German Military Hospital Berlin
 

Prof Ran Nir-Paz

Associate Professor of Medicine
Hadassah-Hebrew University Medical Centre

"I am an Infectious Diseases physician at the Hadassah Hebrew University Medical Center in Jerusalem, Israel. As part of the Infectious Diseases service I support our arthroplasty service which is a referral center from around Israel for the more complicated cases. With that I encounter many patients who have infections which are either chronic or hard to cure using common antibiotics. In order to tackle that we have created an ad-hoc compassionate/ early clinical trial phage treatment center with the Hazan [email protected].

Prof Ran Nir-Paz

Associate Professor of Medicine
Hadassah-Hebrew University Medical Centre

Prof Ran Nir-Paz

Associate Professor of Medicine
Hadassah-Hebrew University Medical Centre

"I am an Infectious Diseases physician at the Hadassah Hebrew University Medical Center in Jerusalem, Israel. As part of the Infectious Diseases service I support our arthroplasty service which is a referral center from around Israel for the more complicated cases. With that I encounter many patients who have infections which are either chronic or hard to cure using common antibiotics. In order to tackle that we have created an ad-hoc compassionate/ early clinical trial phage treatment center with the Hazan [email protected] We already successfully treated one patient and few more are on the way."

 

Dr David Harper

CEO and CSO
Evolution Biotechnologies

My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.

Dr David Harper

CEO and CSO
Evolution Biotechnologies

Dr David Harper

CEO and CSO
Evolution Biotechnologies

My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.

Targets include the house dust mite, the main cause of asthma, where our novel approach underlies broad patent protection, and antibiotic resistant bacterial infections where individual veterinary treatments are already being undertaken. The company is building on its unique skillset in these key areas.

 

Dr Kimberley Bishop-Lilly

Deputy Head, Genomics & Bioinformatics Dept
Naval Medical Research Center - Frederick

Dr Kimberley Bishop-Lilly

Deputy Head, Genomics & Bioinformatics Dept
Naval Medical Research Center - Frederick

Dr Kimberley Bishop-Lilly

Deputy Head, Genomics & Bioinformatics Dept
Naval Medical Research Center - Frederick
 

Dr Ben Burrowes

Consultant
Evolution Biotechnologies

Dr Ben Burrowes

Consultant
Evolution Biotechnologies

Dr Ben Burrowes

Consultant
Evolution Biotechnologies

POSTER SESSION

Looking to showcase your recent work to the phage therapy community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

Poster abstract submission deadline is on 17th July 2019. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

For more information please contact [email protected]



SUBMISSIONS ARE NOW CLOSED



Event Partners

Lead Media Partner

Media Partners

The Agenda

Please download our agenda to find out more information about the congress including the main topics of discussion for the two days and preview lineup of speakers.

What you can expect from the Europe 2019 congress:

  • 150+ participants from academic, industry, biotech and regulatory bodies onsite
  • 25+ European and global phage thought leaders on the speaking agenda and ready to answer your big questions
  • 2 days of furthering phage therapy

Phage Futures Europe

Download Agenda

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

Venue

Pullman Brussels Centre Midi, Place Victor Horta 1, 1060 Brussels, Belgium

Phage Futures Europe

PULLMAN BRUSSELS CENTRE MIDI

PLACE VICTOR HORTA 1

1060 BRUSSELS – BELGIUM

Special room rate: EUR 275 per night including Breakfast (excluding city tax).

In order to make your reservation, the hotel kindly asks that you complete the booking form

DOWNLOAD THE HOTEL ROOM BOOKING FORM HERE

https://kisacoresearch.com/content/pullman-brussels-centre-midi-room-booking-form

This must be completed and sent to [email protected] before 24-08-2019

After this date, the availability of the rooms or the proposed rates, is no longer guaranteed.

Any late reservation request will be treated following availability.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Worldpay:
Saturday, June 15, 2019 to Friday, July 26, 2019
Early Bird - Standard (Pharmaceutical, Large Biotechs & Service Providers)
€1999 + VAT
Early Bird available through July 26, 2019. Save €300.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, June 15, 2019 to Friday, July 26, 2019
Early Bird - Small Biotech (Under 30 Employees)
€1399 + VAT
Early Bird available through 26 July, 2019. Save €300.
Must have an active drug pipeline
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, June 15, 2019 to Friday, July 26, 2019
Early Bird - Academics, Government & Clinicians
€699 + VAT
Early Bird available through 26 July, 2019. Save €100.
Must be a full time academic or healthcare professional
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Wednesday, April 24, 2019 to Thursday, September 26, 2019
Student Rate
€399 + VAT
To claim this rate please contact [email protected]
Students must provide evidence of full-time education
Students must submit a poster to be eligible for the student rate.
For more information please contact [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.